Knight Therapeutics Inc. (GUD.TO)
Toronto - Toronto Real Time Price. Currency in CAD
Add to watchlist
At close: 04:00PM EDT
| Previous Close | 5.68 |
| Open | 5.68 |
| Bid | 5.67 x 0 |
| Ask | 5.71 x 0 |
| Day's Range | 5.65 - 5.72 |
| 52 Week Range | 4.35 - 6.22 |
| Volume | |
| Avg. Volume | 56,062 |
| Market Cap | 578.857M |
| Beta (5Y Monthly) | 0.49 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.16 |
| Earnings Date | Aug 08, 2024 - Aug 12, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.19 |
Simply Wall St.Knight Therapeutics Inc. (TSE:GUD) stock most popular amongst individual investors who own 40%, while private companies hold 25%
Key Insights Knight Therapeutics' significant individual investors ownership suggests that the key decisions are...
GlobeNewswireKnight Announces Normal Course Issuer Bid
MONTREAL, July 11, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) ("Knight" or the "Company "), a leading pan-American (ex-US) specialty pharmaceutical company, announced today acceptance by the Toronto Stock Exchange (the "TSX") of the Company's Notice of Intention to Make a Normal Course Issuer Bid ("NCIB"). Pursuant to the NCIB, the Company proposes to purchase, from time to time over the next 12 months, if considered advisable, up to 5,312,846 common shares of the Company, being
Simply Wall St.Knight Therapeutics First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Knight Therapeutics ( TSE:GUD ) First Quarter 2024 Results Key Financial Results Revenue: CA$86.6m (up 4.9% from 1Q...
© 2024 Yahoo. All rights reserved.